Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials

Maraviroc blocks HIV-1 entry into CD4+ cells by interrupting the interaction between viral gp120 and cell-surface CCR5. Resistance to CCR5 antagonist–mediated inhibition can develop by unmasking pre-existing CXCR4-using virus or through selection of CCR5-tropic resistant virus, characterized by plat...

Descripción completa

Detalles Bibliográficos
Autores principales: Jubb, Becky, Lewis, Marilyn, McFadyen, Lynn, Simpson, Paul, Mori, Julie, Chan, Phylinda, Weatherley, Barry, van der Ryst, Elna, Westby, Mike, Craig, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931239/
https://www.ncbi.nlm.nih.gov/pubmed/31856576
http://dx.doi.org/10.1177/2040206619895706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931239/
https://www.ncbi.nlm.nih.gov/pubmed/31856576
http://dx.doi.org/10.1177/2040206619895706

Ejemplares similares